Breaking News
Get 40% Off 0
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks. Unlock full list
Close

Renalytix AI plc (RENX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
19.50 -2.00    -9.30%
22/05 - Closed. Currency in GBP ( Disclaimer )
  • Volume: 229,524
  • Bid/Ask: 19.00 / 22.00
  • Day's Range: 18.00 - 20.00
Type:  Equity
Market:  United Kingdom
ISIN:  GB00BYWL4Y04 
SEDOL:  BYWL4Y0
Renalytix AI 19.50 -2.00 -9.30%

Renalytix AI Company Profile

 
Read the Renalytix AI plc company profile to learn more about the business and the management team. View Renalytix AI plc facts about employee data, company products and services, and contact information.
IndustryHealthcare Equipment & Supplies
SectorHealthcare
Employees

102

Equity Type

ORD

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.

Contact Information

Address 1460 Broadway
New York, 10036
United States
Phone 646 397 3970
Fax -

Top Executives

Name Age Since Title
Christopher Harwood-Bernard Mills 71 2018 Independent Non-Executive Chairman
Daniel Joseph Levangie 73 2021 Independent Non-Executive Director
Erik K. Lium 56 2018 Independent Non-Executive Director
Catherine Coste 57 2023 Independent Non-Executive Director
Eugene E. Wright - 2023 Member of Clinical Advisory Board
Joseph A. Vassalotti - 2019 Member of Clinical Advisory Board
Barry I. Freedman - - Member of Clinical Advisory Board
Matthew Jay Budoff - 2023 Member of Clinical Advisory Board
Javier Morales - 2023 Member of Clinical Advisory Board
Stephen Brunton - 2023 Member of Clinical Advisory Board
Ralph A. Defronzo - 2023 Member of Clinical Advisory Board
Holly J. Mattix-Kramer - 2023 Member of Clinical Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

RENX Price Commentary

Write your thoughts about Renalytix AI plc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email